Research progress onneoadjuvant therapy in stage ⅢA-N2 non-small cell lung cancer / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
; (6): 61-64, 2020.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-798809
Responsible library:
WPRO
ABSTRACT
ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Radiation Oncology
Year:
2020
Document type:
Article